These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Early childhood developmental follow-up of infants with GMH/IVH: effect of methylxanthine therapy. Ment LR; Scott DT; Ehrenkranz RA; Duncan CC Am J Perinatol; 1985 Jul; 2(3):223-7. PubMed ID: 4015773 [TBL] [Abstract][Full Text] [Related]
4. The effects of caffeine on heart rate variability in newborns with apnea of prematurity. Ulanovsky I; Haleluya NS; Blazer S; Weissman A J Perinatol; 2014 Aug; 34(8):620-3. PubMed ID: 24722649 [TBL] [Abstract][Full Text] [Related]
5. Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups. M S; Nayak K; Lewis LES; Kamath A; Purkayastha J J Trop Pediatr; 2019 Jun; 65(3):264-272. PubMed ID: 30085175 [TBL] [Abstract][Full Text] [Related]
6. Methylxanthine therapy in premature infants: sound practice, disaster, or fruitless byway? Schmidt B J Pediatr; 1999 Oct; 135(4):526-8. PubMed ID: 10518091 [No Abstract] [Full Text] [Related]
7. Current options in the management of apnea of prematurity. Bhatia J Clin Pediatr (Phila); 2000 Jun; 39(6):327-36. PubMed ID: 10879934 [TBL] [Abstract][Full Text] [Related]
8. Doxapram versus methylxanthine for apnea in preterm infants. Henderson-Smart DJ; Steer P Cochrane Database Syst Rev; 2000; (2):CD000075. PubMed ID: 10796115 [TBL] [Abstract][Full Text] [Related]
9. Evidence-based methylxanthine use in the NICU. Spitzer AR Clin Perinatol; 2012 Mar; 39(1):137-48. PubMed ID: 22341542 [TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of apnoea in preterm infants. Ruggins NR Arch Dis Child; 1991 Jan; 66(1 Spec No):70-3. PubMed ID: 1996899 [No Abstract] [Full Text] [Related]
12. Maturation of the autonomic nervous system: differences in heart rate variability in premature vs. term infants. Longin E; Gerstner T; Schaible T; Lenz T; König S J Perinat Med; 2006; 34(4):303-8. PubMed ID: 16856820 [TBL] [Abstract][Full Text] [Related]
13. Letter: The use of xanthines in treating apnea of prematurity. Kuzemko JA Pediatrics; 1976 Feb; 57(2):293. PubMed ID: 1250669 [No Abstract] [Full Text] [Related]
15. Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. Schmidt B Biol Neonate; 2005; 88(3):208-13. PubMed ID: 16210843 [TBL] [Abstract][Full Text] [Related]
16. Autonomic nervous system activity in premature and full-term infants from theoretical term to 7 years. De Rogalski Landrot I; Roche F; Pichot V; Teyssier G; Gaspoz JM; Barthelemy JC; Patural H Auton Neurosci; 2007 Oct; 136(1-2):105-9. PubMed ID: 17556047 [TBL] [Abstract][Full Text] [Related]
17. [Development of plasma xanthine levels in the treatment of apnea in premature infants]. Brazier JL; Renaud H; Ribon B; Faucon G; Sassard J Therapie; 1978; 33(3):341-55. PubMed ID: 684686 [No Abstract] [Full Text] [Related]
18. The Effect of Gestational Age at Birth on Post-Term Maturation of Heart Rate Variability. Fyfe KL; Yiallourou SR; Wong FY; Odoi A; Walker AM; Horne RS Sleep; 2015 Oct; 38(10):1635-44. PubMed ID: 25902805 [TBL] [Abstract][Full Text] [Related]
19. Letter: The use of xanthines in treating apnea of prematurity. Morens DM Pediatrics; 1975 Oct; 56(4):617-9. PubMed ID: 1165973 [No Abstract] [Full Text] [Related]
20. Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. Abu Jawdeh EG; O'Riordan M; Limrungsikul A; Bandyopadhyay A; Argus BM; Nakad PE; Supapannachart S; Yunis KA; Davis PG; Martin RJ J Neonatal Perinatal Med; 2013; 6(3):251-6. PubMed ID: 24246598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]